SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% – Time to Sell?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s share price dropped 5.5% on Thursday . The company traded as low as $3.89 and last traded at $3.8850. Approximately 1,619,858 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 15,726,965 shares. The stock had previously closed at $4.11.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.00.

SELLAS Life Sciences Group Price Performance

The stock has a market cap of $569.05 million, a price-to-earnings ratio of -14.27 and a beta of 2.26. The stock’s 50 day simple moving average is $2.49 and its two-hundred day simple moving average is $2.05.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. As a group, analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current year.

Insider Activity at SELLAS Life Sciences Group

In other news, Director Katherine Bach Kalin bought 63,400 shares of the company’s stock in a transaction dated Wednesday, November 19th. The stock was bought at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the completion of the transaction, the director directly owned 104,400 shares in the company, valued at $165,996. The trade was a 154.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On SELLAS Life Sciences Group

A number of hedge funds and other institutional investors have recently made changes to their positions in SLS. Jaffetilchin Investment Partners LLC bought a new stake in shares of SELLAS Life Sciences Group in the 4th quarter valued at $92,000. SG Americas Securities LLC lifted its holdings in shares of SELLAS Life Sciences Group by 88.2% during the 4th quarter. SG Americas Securities LLC now owns 36,450 shares of the company’s stock valued at $137,000 after purchasing an additional 17,084 shares in the last quarter. Dagco Inc. acquired a new position in shares of SELLAS Life Sciences Group in the 4th quarter valued at approximately $2,177,000. Everhart Financial Group Inc. increased its stake in SELLAS Life Sciences Group by 40.8% during the 4th quarter. Everhart Financial Group Inc. now owns 466,216 shares of the company’s stock worth $1,758,000 after purchasing an additional 135,066 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in SELLAS Life Sciences Group by 21.9% during the 3rd quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock worth $68,000 after buying an additional 7,571 shares during the period. 17.38% of the stock is owned by institutional investors.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.